Korean Surgical Robot Startup Hits $1B Valuation

LivsMed, a surgical robotics company from Seoul, just became a billion-dollar business with a bold promise: making advanced surgery available to everyone, everywhere.

The company raised $94 million through its public stock offering on Korea's KOSDAQ market last week. With a market value now topping $1 billion, LivsMed joins the elite club of medical technology unicorns.

The funds will help build production facilities and accelerate research for its STARK surgical robot system. The system allows surgeons to perform minimally invasive procedures with precision controls that mimic natural hand movements.

"An innovation cannot be called an innovation unless it can reach the masses," said Dr. Jung Joo Lee, LivsMed's founder and CEO. That philosophy drives everything from their robot design to their global expansion strategy.

In July 2025, LivsMed showed just how far surgical care could reach. A surgeon in Santa Barbara, California, successfully controlled the STARK robot in Chicago, proving that expert surgical care could travel across time zones and state lines.

The company isn't stopping with robots. Since 2018, LivsMed has been developing handheld surgical instruments that give surgeons wrist-like flexibility during procedures. Their newest tool, ArtiSeal, bends at 90-degree angles to reach tight spaces inside the body that traditional instruments struggle to access.

Investors clearly see the potential. The offering attracted 231 times more demand than available shares, with interest pouring in from pension funds and financial institutions across the U.S., Middle East, and Asia.

The Ripple Effect

When advanced surgical capabilities spread beyond major medical centers, rural communities and underserved regions gain access to life-saving procedures. Remote surgery technology means a world-class surgeon in Boston could guide a procedure in a small-town hospital thousands of miles away. LivsMed's systems are helping turn that vision into reality, one procedure at a time.

The company operates from Seoul with a U.S. office in San Diego, positioning itself to serve patients across continents. While the STARK system still needs U.S. approval, its successful demonstrations show the technology works.

Making surgical innovation accessible isn't just good medicine; it's closing healthcare gaps that have existed for generations.